Comments
Divis Laboratories has said that its facility near Hyderabad has been inspected by the US health regulator for pre-approval of products to be established and sold by the unit, and current good manufacturing practices.
The company had “an inspection by the USFDA, with no major observations’’, for unit 1 of the project during July 2011, Divis Laboratories said in a filing to the Bombay Stock Exchange today.
“The audit concluded with minor observations primarily about additional records for further improvement of existing records,” it added.
Meanwhile, the company shares were today trading at Rs 807.50 in the afternoon trade on the BSE, down 1.04 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.